Trial · NCT01389596
Results by group186
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 186
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | 3.27 | Standard Deviation 1.215 | Seizures per 28 days | |
| Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | 3.19 | Standard Deviation 1.269 | Seizures per 28 days | |
| Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase | Placebo | 3.18 | Standard Deviation 1.302 | Seizures per 28 days | |
| Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During 12-Week Treatment Phase | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | 2.86 | Standard Error 0.070 | Seizures per 28 days | |
| Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During 12-Week Treatment Phase | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | 2.74 | Standard Error 0.072 | Seizures per 28 days | |
| Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During 12-Week Treatment Phase | Placebo | 2.96 | Standard Error 0.073 | Seizures per 28 days | |
| Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Seizure Rate During the 12 Week Treatment Phase | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | 29.1 | percentage of participants | ||
| Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Seizure Rate During the 12 Week Treatment Phase | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | 40.6 | percentage of participants | ||
| Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Seizure Rate During the 12 Week Treatment Phase | Placebo | 22.6 | percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | AEs | 67 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | AEs | 68 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | AEs | 56 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | SAEs | 5 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | SAEs | 10 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | SAEs | 7 | participants | |
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | AEs | 37 | participants | |
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | AEs | 46 | participants | |
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | AEs | 30 | participants | |
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 2.5 mg/kg/Day or 3.5 mg/kg/Day | SAEs | 1 | participants | |
| Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) | Pregabalin: 10 mg/kg/Day or 14 mg/kg/Day | SAEs | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01389596/results